...and one other area that i forgot to mention that I still like about this companies chances for success.
Please correct me if I'm wrong, but hasn't the company postioned Vaxinia, Oncarytics and Azer Cell, not as a competitor to 1st line, 2nd line, 3rd line, or any other approved treatment, but rather at the end, when patients have fallen off all lines of treatment, like the 60% that fall off the time consuming process of Autogulous trearment for blood cancers, and where there is currently no further treatments available.
When the Dr says I'm sorry there is nothing more we can do. This therapeutics space is vacant, the patient is out of options. Go home and get your affairs in order. Aren't we trying to fill that space to offer them an already approved CarT with CF33 carrying CD 19 protiens, thats off the shelf available straight away. Who is our competitor at the end of the therapy line, particularly with Bile Duct cancer?
Isn't that part of the reason that we received Fast Track and Orphan Status, because no one is there.
The MAST study results on low to medium dose was pretty good. Hopefully this next Vaxinia data drop on medium to OBD dose on the most responsiver cancer is far better than the low dose random MAST data, which was great anyway. I vaguely remember a LC video with Dr ?? where they discussed the MAST data, and he was hoping for 10-20 patients in the Bile Duct Vaxinia study and stated he hoped for 30-50% over all response rate, or something like that. I like our odds.
For these reasons i like the company and its chances of success. If it does drop in the mean time, ill buy some more.
Back to my cave until the data drops.
God bless everyone on here, especially those with or effected by cancer.
IMU Price at posting:
3.6¢ Sentiment: Hold Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)